FDA 483 - Laurus Labs Limited - January 31, 2025

During an inspection conducted by the U.S. Food and Drug Administration (FDA) from January 27 to January 31, 2025, at Laurus Labs Limited, an Active Pharmaceutical Ingredient (API) manufacturer located in Anakapalli District, Andhra Pradesh, India, significant observations were noted regarding the firm's quality management system. The primary issue identified was a failure to ensure that equipment qualification protocols were appropriately reviewed and approved by the quality unit. Specifically, FDA investigators observed that multiple pieces of manufacturing equipment, essential for producing various active pharmaceutical ingredients, had been qualified without an approved protocol. This indicates a lapse in adherence to established internal procedures designed to maintain the integrity and reliability of manufacturing processes. While the FDA Form 483 document itself details these observations without specifying immediate required actions, it serves as a formal communication of potential deviations from current good manufacturing practices. Laurus Labs Limited is therefore expected to thoroughly investigate these findings, implement comprehensive corrective and preventive actions, and demonstrate that all equipment qualification processes are rigorously reviewed and approved by the quality unit to ensure compliance with regulatory standards and safeguard product quality and patient safety.